What is HC Wainwright’s Estimate for LSTA FY2024 Earnings?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Investment analysts at HC Wainwright lifted their FY2024 earnings estimates for Lisata Therapeutics in a research report issued to clients and investors on Thursday, November 21st. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($2.64) for the year, up from their prior estimate of ($2.99). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Lisata Therapeutics’ Q4 2024 earnings at ($0.79) EPS, FY2025 earnings at ($1.83) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at ($1.26) EPS.

Lisata Therapeutics Price Performance

LSTA stock opened at $2.88 on Monday. The firm has a market cap of $24.16 million, a price-to-earnings ratio of -1.15 and a beta of 1.22. Lisata Therapeutics has a twelve month low of $2.05 and a twelve month high of $3.83. The business’s fifty day simple moving average is $2.93 and its two-hundred day simple moving average is $3.09.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.16. During the same period in the previous year, the company earned ($0.65) earnings per share.

Hedge Funds Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP increased its position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned 0.21% of Lisata Therapeutics worth $60,000 as of its most recent SEC filing. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.